Shivaani Kummar
Oregon Health & Science University(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research
Most-Cited Works
- → Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children(2018)2,654 cited
- → Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials(2020)963 cited
- → SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study(2018)333 cited
- → Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies(2009)328 cited
- → Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer(2019)326 cited
- → Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors(2015)318 cited
- → Wee1 kinase as a target for cancer therapy(2013)267 cited
- → Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas(2011)252 cited
- → Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors(2023)220 cited
- → Cediranib for Metastatic Alveolar Soft Part Sarcoma(2013)218 cited